Predictive Oncology (NASDAQ:AGPU) Rating Lowered to Sell at Wall Street Zen

Predictive Oncology (NASDAQ:AGPU) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Monday.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Predictive Oncology in a report on Friday, April 24th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, Predictive Oncology currently has a consensus rating of “Sell”.

Predictive Oncology Stock Performance

Shares of NASDAQ:AGPU opened at $6.97 on Monday. The stock’s 50 day simple moving average is $4.68. Predictive Oncology has a 12-month low of $1.03 and a 12-month high of $32.10. The firm has a market cap of $72.49 million, a price-to-earnings ratio of -0.85 and a beta of 3.47.

Predictive Oncology (NASDAQ:AGPU) last issued its quarterly earnings results on Friday, May 15th. The company reported ($0.36) earnings per share (EPS) for the quarter. The company had revenue of $0.04 million during the quarter. Predictive Oncology had a negative net margin of 470,383.31% and a negative return on equity of 7,363.67%.

Predictive Oncology Company Profile

Predictive Oncology (NASDAQ: AGPU) is a biotechnology company focused on oncology-related research and product development that combines laboratory science with data analytics. The company positions itself to support precision medicine by applying computational methods and laboratory testing to better understand tumor biology and to accelerate the identification and development of oncology therapeutics and diagnostics.

Its activities include laboratory-based testing and analytic services intended to inform drug discovery and development, biomarker identification, and patient stratification efforts.